Archive for September, 2009

Calcium and Colorectal Cancer

Friday, September 4th, 2009

logo1267406_md2

A new study by the National Institutes of Health and AARP found that people who consume more calcium and dairy foods have a lower risk of colon cancer. Diet and other information was collected on over 50,000 people between the ages of 50 and 71. After 7 years the risk of colon cancer was about 20% lower in men who consumed the most calciuim from food and supplements (about 1,500 mg. daily) than in men who consumed the least (about 500mg daily).

The risk in women was about 30% lower for women who consumed the most calcium (about 1,900 mg daily) that those who consumed the least (about 500 mg daily). Colorectal cancer was also lower in men and women who ate the most daily foods. However, contract to earlier stuidies dairy was not linked to a higher risk of ovarian cancer and calcium was not linked to a higher risk of prostate cancer.

It is best to try to ingest 1,000 mg daily of calcium if you are under 50 and 1,200 mg daily if you are older. If you assume there is 300 mg in each serving of milk, cheese, yogurt, or calcium-fortified orange juice take a supplement to get any additional calcium needed. In light of the earlier studies of calcium and prostate cancer (not found here) men may want to limit intake of calcium to 1,200 mg daily. Additional information can be found in the Archives of Internal Medicine, 169:391, 2009.

Wednesday, September 2nd, 2009

BBS Show September 12 at 10 p.m. EST with guests Dr Arlene Donar and Dr Francisco Contreras.

Estrogen and Breast Cancer Treatment

Wednesday, September 2nd, 2009

logo1267406_md1

In a study published in the Journal of the American medical Assn (JAMA) on August 19, 2009 researchers at Washington School of Medicine confirmed previous known kinowledge that estrogen can be used to treat metastatic hormone-dependent breast cancer in postmenopausal women. In their study Dr Matthew Ellis and colleagues studied 66 women with advanced stages of breast cancer and were being treated with Pfizer’s Aromasin, Novartis’s Femara, and AstraZeneca Pic’s Arimidex which are all new drugs for breast cancer. They had all experienced a relapse while on estrogen-lowering drugs, and their disease was progressing so they were faced with undergoing chemotherapy. The researchers found that estrogen treatment in the form of estradiol stopped the progression of the disease in many women and was much better tolerated than chemotherapy would have been.
Estradiol was given in both high and low doses and 30% showed signs of improvement. They found that giving low doses showed better recovery compared to high doses and there were fewer negative side effects. They concluded that low does of estrogen may help cure certain types of breast cancer and more research is planned.

More information is available in the August 19, Vol 302, No 7 issue of JAMA.